NEW YORK, July 19, 2010 (GLOBE NEWSWIRE) -- HepaLife™ Technologies, Inc. (OTCBB:HPLF) (the “Company” or “HepaLife™") recently completed its acquisition of AquaMed HepaLife™ Technologies, Inc. (“AquaMed”), a developer of transdermal patches. AquaMed’s sheet hydrogels, which are the basis for AquaMed’s patch technology, will complement the Company’s existing HepaMate™ liver technology. Matthew Harriton, CEO of AquaMed, commented, “AquaMed’s patch technology enables the delivery of drugs and active ingredients directly through the stratum corneum avoiding ‘first pass’ of the digestive system and the liver. We believe that delivering drugs this way reduces stress on the liver and helps reduce the chance of liver complications. HepaLifeTM, by expanding its portfolio with this acquisition, is now positioned to address the full spectrum of liver care, from preventative to curative.”
